ATLANTA, GA – – (Newsfile Corp. – February 2, 2021) – – Holzer & Holzer, LLC is investigating whether Immunovant, Inc. (“Immunovant” or the “Company”) (NASDAQ: IMVT) complied with federal securities laws. On February 2, 2021, the Company announced it had decided to voluntarily pause dosing in ongoing clinical studies in both Thyroid Eye Disease and Warm Autoimmune Hemolytic Anemia after it had “become aware of a physiological signal consisting of elevated total cholesterol and LDL levels in IMVT-1401-treated patients.” The price of Immunovant’s stock fell following the announcement. If you purchased shares of Immunovant and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at email@example.com or Luke R. Kennedy, Esq. at firstname.lastname@example.org, or by toll-free telephone at (888) 508-6832 to discuss your legal rights or at www.holzerlaw.com.